Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/03/24
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”GlobeNewsWire • 03/26/24
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/07/24
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024GlobeNewsWire • 02/29/24
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewsWire • 01/31/24
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERDGlobeNewsWire • 12/06/23
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated HeartburnGlobeNewsWire • 11/28/23
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business UpdatesGlobeNewsWire • 11/09/23
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in AdultsGlobeNewsWire • 11/01/23
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in AdultsGlobeNewsWire • 10/30/23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)PRNewsWire • 10/24/23
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERDGlobeNewsWire • 09/26/23
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug ApplicationGlobeNewsWire • 08/21/23
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERDGlobeNewsWire • 06/12/23
Phathom Pharmaceuticals Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common StockGlobeNewsWire • 06/09/23
PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities LawsPRNewsWire • 06/09/23